Royalty Pharma plc (RPRX) is overvalued and we do not publish a verdict for Revolution Medicines Inc (RVMD).
We publish an intrinsic value for RPRX but not for RVMD, so the two cannot be ranked on price.
Values as of the 22 Sept 2026 close.
Discounting its cash flows at 7.7% (average of 3 methods) values the shares at $39.27; the price of $58.52 is 49% above that value, and 80% of that value comes from beyond year five.
Leak Score 34/100 on 7 of 12 signals
No Leak Score yet
| Metric | RPRX | RVMD |
|---|---|---|
| Verdict | Overvalued | — |
| Price | $58.52 | $192.86 |
| Intrinsic value | $39.27 | — |
| Margin of safety | -49% | — |
| Leak Score | 34/100 (7/12) | — |
| Market cap | $33.7B | $41.3B |
| Revenue growth, 5 years | 2.3% | — |
| Operating margin | 62.3% | — |
| Net margin | 32.1% | — |
| Return on equity | 12.4% | -79.1% |
| Debt to equity | 1.31 | 0.46 |
| P/E | 31.1x | — |
| Forward P/E | 10.2x | — |
| P/B | 3.8x | 15.8x |
| Dividend yield | 1.8% | — |